Literature DB >> 19091550

Evaluation of lymph nodes with RECIST 1.1.

L H Schwartz1, J Bogaerts, R Ford, L Shankar, P Therasse, S Gwyther, E A Eisenhauer.   

Abstract

Lymph nodes are common sites of metastatic disease in many solid tumours. Unlike most metastases, lymph nodes are normal anatomic structures and as such, normal lymph nodes will have a measurable size. Additionally, the imaging literature recommends that lymph nodes be measured in the short axis, since the short axis measurement is a more reproducible measurement and predictive of malignancy. Therefore, the RECIST committee recommends that lymph nodes be measured in their short axis and proposes measurement values and rules for categorising lymph nodes as normal or pathologic; either target or non-target lesions. Data for the RECIST warehouse are presented to demonstrate the potential change in response assessment following these rules. These standardised lymph node guidelines are designed to be easy to implement, focus target lesion measurements on lesions that are likely to be metastatic and prevent false progressions due to minimal change in size.

Entities:  

Mesh:

Year:  2008        PMID: 19091550     DOI: 10.1016/j.ejca.2008.10.028

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  78 in total

1.  A practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria.

Authors:  Anne S Tsao; Linda Garland; Mary Redman; Kemp Kernstine; David Gandara; Edith M Marom
Journal:  J Thorac Oncol       Date:  2011-03       Impact factor: 15.609

2.  The role of magnetic resonance imaging in oncology.

Authors:  Concepción González Hernando; Laura Esteban; Teresa Cañas; Enrique Van den Brule; Miguel Pastrana
Journal:  Clin Transl Oncol       Date:  2010-09       Impact factor: 3.405

3.  New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy.

Authors:  Mizuki Nishino; David M Jackman; Hiroto Hatabu; Beow Y Yeap; Leigh-Anne Cioffredi; Jeffrey T Yap; Pasi A Jänne; Bruce E Johnson; Annick D Van den Abbeele
Journal:  AJR Am J Roentgenol       Date:  2010-09       Impact factor: 3.959

4.  What is the pelvic lymph node normal size? Determination from normal MRI examinations.

Authors:  Marjorie Ramirez; Pierre Ingrand; Jean-Pierre Richer; Guillaume Herpe; Guillaume Vesselle; Samy Boucebci; Jean-Pierre Tasu
Journal:  Surg Radiol Anat       Date:  2015-10-29       Impact factor: 1.246

5.  Performance Evaluation of a Newly Developed MR-Compatible Mobile PET Scanner with Two Detector Layouts.

Authors:  Masao Watanabe; Yuji Nakamoto; Ryusuke Nakamoto; Takayoshi Ishimori; Tsuneo Saga; Kaori Togashi
Journal:  Mol Imaging Biol       Date:  2020-04       Impact factor: 3.488

6.  A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma.

Authors:  Julie E Bauman; Hugo Arias-Pulido; Sang-Joon Lee; M Houman Fekrazad; Hiroyuki Ozawa; Elana Fertig; Jason Howard; Justin Bishop; Hao Wang; Garth T Olson; Michael J Spafford; Dennie V Jones; Christine H Chung
Journal:  Oral Oncol       Date:  2013-02-04       Impact factor: 5.337

7.  Comparison of the diagnostic performance of response evaluation criteria in solid tumor 1.0 with response evaluation criteria in solid tumor 1.1 on MRI in advanced breast cancer response evaluation to neoadjuvant chemotherapy.

Authors:  Su Kyung Jeh; Sung Hun Kim; Bong Joo Kang
Journal:  Korean J Radiol       Date:  2012-12-28       Impact factor: 3.500

8.  Quantitative imaging to assess tumor response to therapy: common themes of measurement, truth data, and error sources.

Authors:  Charles R Meyer; Samuel G Armato; Charles P Fenimore; Geoffrey McLennan; Luc M Bidaut; Daniel P Barboriak; Marios A Gavrielides; Edward F Jackson; Michael F McNitt-Gray; Paul E Kinahan; Nicholas Petrick; Binsheng Zhao
Journal:  Transl Oncol       Date:  2009-12       Impact factor: 4.243

9.  Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).

Authors:  T Dragovich; D Laheru; F Dayyani; V Bolejack; L Smith; J Seng; H Burris; P Rosen; M Hidalgo; P Ritch; A F Baker; N Raghunand; J Crowley; D D Von Hoff
Journal:  Cancer Chemother Pharmacol       Date:  2014-06-18       Impact factor: 3.333

10.  [Imaging in oncology: terms and definitions].

Authors:  P Brader; Y Menu; S Kreuzer; S Polanec; M Mayerhoefer; C J Herold
Journal:  Radiologe       Date:  2013-04       Impact factor: 0.635

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.